These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 1728095)

  • 21. An etiologic approach to management of duodenal and gastric ulcers.
    Rex DK
    J Fam Pract; 1994 Jan; 38(1):60-7. PubMed ID: 8289053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals.
    Brzozowski T; Konturek PC; Sliwowski Z; Kwiecień S; Drozdowicz D; Pawlik M; Mach K; Konturek SJ; Pawlik WW
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():67-79. PubMed ID: 17033106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials.
    Rostom A; Wells G; Tugwell P; Welch V; Dubé C; McGowan J
    J Rheumatol; 2000 Sep; 27(9):2203-14. PubMed ID: 10990235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression.
    Lad R; Armstrong D
    Can J Gastroenterol; 1999 Mar; 13(2):135-42. PubMed ID: 10203432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
    Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
    Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
    Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms.
    Laine L
    Rev Gastroenterol Disord; 2003; 3 Suppl 4():S30-9. PubMed ID: 14671512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials.
    Koch M; Dezi A; Ferrario F; Capurso I
    Arch Intern Med; 1996 Nov; 156(20):2321-32. PubMed ID: 8911239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ulcer prevention during anti-rheumatism therapy and in intensive medicine].
    Koelz HR
    Schweiz Rundsch Med Prax; 1994 Jun; 83(25-26):768-71. PubMed ID: 8029591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rheumatologists' adherence to guidelines for misoprostol use in patients at high risk for nonsteroidal antiinflammatory drug gastropathy.
    Cibere J; Sibley JT; Haga M
    J Rheumatol; 2002 Feb; 29(2):339-46. PubMed ID: 11838854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of anti-ulcerative drugs in treatment and prevention of gastropathies induced by nonsteroidal anti-inflammatory drugs].
    Fialová P; Vlcek J
    Vnitr Lek; 2004 Nov; 50(11):858-66. PubMed ID: 15648967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonsteroidal anti-inflammatory drug use in dentistry: gastrointestinal implications.
    Nguyen AM; Graham DY; Gage T; Griffiths GR
    Gen Dent; 1999; 47(6):590-6; quiz 597-8. PubMed ID: 10687453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy.
    Lanas A; Remacha B; Sáinz R; Hirschowitz BI
    Am J Gastroenterol; 2000 Feb; 95(2):513-9. PubMed ID: 10685760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment and prevention of NSAID induced gastroduodenal mucosal damage.
    Agrawal NM; Saggioro A
    J Rheumatol Suppl; 1991 Mar; 28():15-8. PubMed ID: 1674754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptic ulcer disease today.
    Yuan Y; Padol IT; Hunt RH
    Nat Clin Pract Gastroenterol Hepatol; 2006 Feb; 3(2):80-9. PubMed ID: 16456574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial.
    de Leest HT; Steen KS; Lems WF; Bijlsma JW; van de Laar MA; Huisman AM; Vonkeman HE; Houben HH; Kadir SW; Kostense PJ; van Tulder MW; Kuipers EJ; Boers M; Dijkmans BA
    Helicobacter; 2007 Oct; 12(5):477-85. PubMed ID: 17760715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Helicobacter pylori infection and the use of NSAIDs.
    Bazzoli F; De Luca L; Graham DY
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):775-85. PubMed ID: 11566040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
    Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
    Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [NSAID ulcer (H. pylori, treatment, prevention)].
    Ohta S; Arai S; Imai Y; Banba H
    Nihon Rinsho; 2004 Mar; 62(3):505-11. PubMed ID: 15038095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention and treatment of nonsteroidal anti-inflammatory drug-induced gastropathy.
    Lee M
    South Med J; 1995 May; 88(5):507-13. PubMed ID: 7732438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.